explore -WSS

explore

author：focus 2025-10-03 01:02:57 - browse：62

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： PBM reforms clear House panel

WSS

PBM reforms clear House panel

The problem with charging patients to message their doctors

Precocious puberty in girls comes with mental health risks

The drug industry has found itself all alone in Washington

Congress must reauthorize a committee to support older Americans

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

leisure time

explore

focus

Hepatitis C has a cure — but many Americans still lack access to it

David Sabatini, ex

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Peter Hotez and the public health issue of online harassment

The Readout: Amylyx, Alumis, and Lundbeck drug updates

New air purifier tech could be key to improving indoor air quality

Sen. Paul opposes bill to ban Chinese biotechs

Medicare details structure of new drug price negotiation program

Does good food count as health care? Study aims to find out

hotspot

Readout LOUD podcast: A CRISPR milestone, biotech mixology

How to bring more disabled researchers into academia

Astellas still sees hope in its gene therapy after four deaths

What it’s like to watch children die of measles

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Change Healthcare payments predicted restored March 15

focus

Wikipedia

hotspot

knowledge